Topical Tranexamic Acid Reduces Blood Loss in Minimally Invasive Total Knee Arthroplasty Receiving Rivaroxaban
Table 1
Characteristics of the patients.
Characteristics
Placebo
IV
Topical
Age (yr) (SD; range)
70.87 (6.05; 59–81)
69.13 (7.94; 51–85)
69.66 (5.53; 59–84)
0.575
BMI (kg/m2) (SD; range)
28.26 (4.84; 19.9–39.8)
28.14 (4.53; 20.6–42.1)
28.40 (5.38; 21.2–49.0)
0.980
Women (%)
24 (80.0%)
27 (87.1%)
19 (59.4%)
0.029
Preoperative Hb (g/dL) (SD; range)
13.04 (1.03; 9.5–15.3)
13.37 (0.98; 9.5–16.8)
13.27 (1.35; 11.1–16.8)
0.518
Preoperative Hct (%) (SD; range)
39.44 (2.78; 30.0–45.3)
40.08 (2.97; 30.0–50.8)
39.60 (3.67; 32.4–48.1)
0.551
PT (SD; range)
10.31 (0.36; 9.6–11.1)
10.21 (0.41; 9.5–12.2)
10.31 (0.44; 9.7–12.2)
0.611
APTT (SD; range)
27.27 (2.12; 22.9–32.8)
26.97 (2.32; 21.3–33.1)
26.89 (2.02; 22.8–33.1)
0.763
Platelet count (1000/μL) (SD; range)
225.30 (50.85; 125–308)
231.26 (72.09; 106–442)
229.50 (46.70; 151–337)
0.918
ASA—number/total number (%)
0.210
I
1/30 (3.3%)
1/31 (3.2%)
0/32 (0.0%)
II
24/30 (80.0%)
22/31 (71.0%)
19/32 (59.4%)
III
4/30 (13.3%)
8/31 (25.8%)
13/32 (40.6%)
SD: standard deviation; APTT: activated partial thromboplastin time; ASA: American Society of Anesthesiologists; BMI: body mass index; INR: interactional normalized ratio; PT: prothrombin time; Hb: hemoglobin; Hct: hematocrit; for all characteristics of patients between all groups, with the exception of gender distribution, the percentage of female patients in the topical group being lower than the percentages in the placebo and IV groups ().
